AbbVie Files 2024 10-K

Ticker: ABBV · Form: 10-K · Filed: Feb 14, 2025 · CIK: 1551152

Abbvie Inc. 10-K Filing Summary
FieldDetail
CompanyAbbvie Inc. (ABBV)
Form Type10-K
Filed DateFeb 14, 2025
Risk Levelmedium
Pages14
Reading Time17 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: 10-K, annual-report, pharmaceuticals

TL;DR

AbbVie's 2024 10-K is in, check financials for the pharma giant.

AI Summary

AbbVie Inc. filed its 2024 10-K on February 14, 2025, detailing its financial performance for the fiscal year ending December 31, 2024. The company, a major player in pharmaceutical preparations, is incorporated in Delaware and headquartered in North Chicago, Illinois. The filing provides comprehensive financial data and business operations information for the period.

Why It Matters

This filing provides investors and analysts with a detailed look at AbbVie's financial health, operational performance, and strategic direction for the past fiscal year, influencing investment decisions.

Risk Assessment

Risk Level: medium — This is a standard annual financial filing providing historical data, not indicating immediate new risks.

Key Players & Entities

  • AbbVie Inc. (company) — Filer of the 10-K
  • 20241231 (date) — Fiscal year end
  • 20250214 (date) — Filing date
  • North Chicago, IL (location) — Company headquarters

FAQ

What is AbbVie Inc.'s primary industry classification?

AbbVie Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.

When was AbbVie Inc.'s 2024 10-K filed with the SEC?

The 10-K was filed on February 14, 2025.

What is the fiscal year end date for AbbVie Inc. in this filing?

The fiscal year end date is December 31, 2024.

Where is AbbVie Inc. headquartered?

AbbVie Inc. is headquartered in North Chicago, IL.

What is the SEC file number for AbbVie Inc.'s 10-K filings?

The SEC file number is 001-35565.

Filing Stats: 4,280 words · 17 min read · ~14 pages · Grade level 15 · Accepted 2025-02-14 13:17:23

Key Financial Figures

  • $0.01 — ich Registered Common Stock, par value $0.01 per share ABBV New York Stock Exchange

Filing Documents

BUSINESS

BUSINESS 1 Item 1A.

RISK FACTORS

RISK FACTORS 14 Item 1B. UNRESOLVED STAFF COMMENTS 25 Item 1C CYBERSECURITY 25 Item 2.

PROPERTIES

PROPERTIES 27 Item 3.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 27 Item 4. MINE SAFETY DISCLOSURES 27 INFORMATION ABOUT OUR EXECUTIVE OFFICERS 28 PART II Item 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 30 Item 6. [RESERVED] 32 Item 7.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 33 Item 7A.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 49 Item 8.

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 50 Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 104 Item 9A.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 104 Item 9B. OTHER INFORMATION 106 Item 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 106 PART III Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 107 Item 11.

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 107 Item 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 108 Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 108 Item 14. PRINCIPAL ACCOUNTING FEES AND SERVICES 108 PART IV Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES 109 Item 16. FORM 10-K SUMMARY 113

SIGNATURES

SIGNATURES 114 PART I

BUSINESS

ITEM 1. BUSINESS Overview AbbVie or "the company" refer to AbbVie Inc., or AbbVie Inc. and its consolidated subsidiaries, as the context requires. AbbVie is a global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio that has leadership positions across immunology, oncology, aesthetics, neuroscience and eye care. AbbVie uses its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie was incorporated in Delaware on April 10, 2012. On January 1, 2013, AbbVie became an independent, publicly-traded company as a result of the distribution by Abbott Laboratories (Abbott) of 100% of the outstanding common stock of AbbVie to Abbott's shareholders. Segments AbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as Chief Operating Decision Maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, development, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods. See Note 16, "Segment and Geographic Area Information" to the Consolidated Financial Sta

View Full Filing

View this 10-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.